Panitumumab
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Panitumumab: From Unknown Original Indication to Drug-Induced Osteoporosis
One-Sentence Summary
Panitumumab is an anti-EGFR monoclonal antibody; its original indication and mechanism of action data are currently unavailable in this evidence pack. The TxGNN model predicts it may be relevant to drug-induced osteoporosis, but this prediction is currently supported by 0 clinical trials and 0 publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (data gap) |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 99.13% |
| Evidence Level | L5 |
| US Market Status | 未上市 (Not Marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, panitumumab is an anti-EGFR monoclonal antibody, and its original approved indication(s) are not captured in this evidence pack.
The proposed link between EGFR-pathway blockade and drug-induced osteoporosis rests on a theoretical connection between EGFR signaling and osteoblast/osteoclast regulation, but no validated mechanistic pathway, clinical data, or literature currently substantiates this connection. This prediction should be treated as a model-generated hypothesis only, not as an evidence-supported repurposing candidate.
A second candidate indication, severe nonproliferative diabetic retinopathy (TxGNN score 99.05%), was also flagged, based on a superficial mechanistic analogy to anti-VEGF therapy in retinal disease. This link is similarly unvalidated and is not supported by any ophthalmology-related trials or literature.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
No U.S. market authorization records available — drug is not currently marketed (未上市).
Cytotoxicity
Panitumumab is a targeted anti-EGFR monoclonal antibody typically used in oncology; however, original indication and DrugBank category data are unavailable in this evidence pack, so cytotoxicity classification cannot be confirmed at this time. Please refer to the package insert warnings and precautions.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication (drug-induced osteoporosis) is supported only by a TxGNN model score (L5 evidence) with no clinical trials, literature, mechanistic data, or safety information available — this is insufficient to justify further evaluation or resource allocation at this time.
To proceed, the following is needed:
- TFDA/FDA label warnings and contraindications (currently blocking — DG001)
- Confirmed mechanism of action and original approved indication(s) (DG002)
- Preclinical or mechanistic studies linking EGFR inhibition to bone metabolism/osteoporosis
- Any clinical trial or case report evidence specific to the predicted indication
- Re-evaluation of the second candidate (severe nonproliferative diabetic retinopathy) if evidence emerges
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.